Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting
Luigi Celio, Francesca Ricchini, Filippo De BraudMedical Oncology Unit 1, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, ItalyAbstract: Control of chemotherapy-induced nausea and vomiting (CINV) is a crucial factor in ensuring that patients undergoing cancer chemo...
Main Authors: | Celio L, Ricchini F, De Braud F |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-05-01
|
Series: | Patient Preference and Adherence |
Online Access: | http://www.dovepress.com/safety-efficacy-and-patient-acceptability-of-single-dose-fosaprepitant-a12979 |
Similar Items
-
Fosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectives
by: Candelario N, et al.
Published: (2016-06-01) -
Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy – results of a non-interventional observation study
by: Semjon Willier, et al.
Published: (2019-11-01) -
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type
by: Cindy Weinstein, et al.
Published: (2020-09-01) -
The Effects of Intravenous Fosaprepitant and Ondansetron for the Prevention of Postoperative Nausea and Vomiting in Neurosurgery Patients: A Prospective, Randomized, Double-Blinded Study
by: Yasuo M. Tsutsumi, et al.
Published: (2014-01-01) -
A Comparison of Fosaprepitant and Ondansetron for Preventing Postoperative Nausea and Vomiting in Moderate to High Risk Patients: A Retrospective Database Analysis
by: Chiaki Murakami, et al.
Published: (2017-01-01)